Healthcare Industry News: HSMN NewsFeed
News Release - April 27, 2017
Allergan Announces Advisory Role for Breast Implant Pioneer Hani ZeiniSientra Founder & Former CEO to contribute to Allergan's World-Class Aesthetic Business
DUBLIN, April 27, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc, a leading global biopharmaceutical company, today announced Hani Zeini has joined the Company as a strategic advisor. In this role, Zeini will advise the Allergan Medical Aesthetics team on strategic business initiatives, as well as, commercial and marketing efforts, and will work directly with David Moatazedi, Senior Vice President of Medical Aesthetics at Allergan.
"We are excited to welcome a true visionary in the industry, Hani Zeini to Allergan's world-class medical aesthetics team," said Moatazedi. "Hani is a pioneer in plastic surgery and has been an industry leader that has helped to shape this exciting and fast growing space. Hani and I share a passion for this specialty. We will be working closely together to shape the future of medical aesthetics remaining laser focused on our vision to double the Aesthetic Market by 2020."
"I am thrilled by this unique opportunity and humbled by such acknowledgment. After nearly two decades in the aesthetics space, my long-term personal goal is to nurture and enhance our plastic surgery ecosystem," said Hani Zeini. "Allergan and I share an unwavering commitment to the specialty and there is no better positioned leader in the aesthetic market for me to partner with in pursuit of our shared values. Allergan's commitment and progressive thinking, as demonstrated through strategic acquisitions, has resulted in a first-in-class innovative aesthetics platform with scale and a breadth of resources. This commitment and vision is what attracted me to partner with Allergan and I look forward to working with David and his team to deliver on these high value, high impact goals."
Mr. Zeini is a successful business leader who in 2006 founded Sientra, a medical device company focused on the Aesthetic and Reconstructive Plastic Surgery markets utilizing implantable silicone technology. He served as Sientra's Chief Executive Officer until 2015, and previously served as Executive Vice President of Inamed Aesthetics, which was subsequently acquired by Allergan. Zeini started his career at the Dupont Pharmaceuticals Company where he spent over 12 years in a variety of positions with increasing responsibility in sales, marketing and general management culminating with his role as Senior Vice President, Global Health Systems. Zeini holds a Bachelor's of Science degree in Electrical and Computer Engineering from the University of Miami in Coral Gables, Florida. In 2003, he completed the Stanford Executive Program at Stanford University, Graduate School of Business.
About Allergan plc
Allergan plc, headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices, surgical and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsFDA Approves Medicines360's sNDA for LILETTA(R) (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Four Years
Amgen and Allergan Submit Biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration
Allergan Successfully Completes ZELTIQ(R) Aesthetics Acquisition